High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids

Keyphrases

• Ascitic Fluid 100%
• High-throughput 100%
• Ovarian Cancer 100%
• Antibody Profile 100%
• Tumor Antigen 75%
• Immunoglobulin 75%
• CREB3L1 75%
• Antibody Response 50%
• Ovarian Cancer Patients 50%
• Clinical Prognosis 25%
• Biomarkers for Early Diagnosis 25%
• Complementary DNA (cDNA) 25%
• Response to Treatment 25%
• Autoantibodies 25%
• Multiple Tumors 25%
• High Sensitivity 25%
• Ascites 25%
• Tumor Treatment 25%
• Prognostic Signature 25%
• Early Response 25%
• Ovarian Cancer Cells 25%
• Fusion Protein 25%
• Non-cancer 25%
• High-throughput Methods 25%
• Phage Display 25%
• Biopanning 25%
• Cancer Research 25%
• Platinum-based Chemotherapy 25%
• Immunoscreening 25%
• Protein Array 25%
• Early Prognosis 25%
• EXOSC10 25%
• Tumor-specific Antibodies 25%
• OLFM4 25%
• HIP1R 25%
• HMGN2 25%
• Antibody Signature 25%

Immunology and Microbiology

• Tumor Antigen 100%
• Immunoglobulin 100%
• Antibody Response 66%
• ELISA 66%
• Autoantibodies 33%
• DNA Library 33%
• Phage Display 33%
• Ovarian Cancer Cell Line 33%
• Biopanning 33%

Medicine and Dentistry

• Ovarian Cancer 100%
• Tumor Antigen 50%
• Malignant Neoplasm 33%
• Enzyme Linked Immunosorbent Assay 33%
• Antibody Response 33%
• Neoplasm 16%
• Biological Marker 16%
• Early Diagnosis 16%
• Autoantibodies 16%
• Cancer 16%
• Proteus Syndrome 16%
• Cancer Treatment 16%
• Ovarian Cancer Cell Line 16%
• Ascites 16%
• Prognostic Signature 16%
• DNA Library 16%
• Protein Microarray 16%
• Chimeric Protein 16%
• Phage Display 16%